paclitaxel has been researched along with Biliary Tract Cancer in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Hwang, JH; Jung, JH; Jung, K; Kim, J; Lee, JC; Park, J | 1 |
| Gou, H; Huang, Q; Li, X; Tan, S; Yang, Y; Zhang, S; Zhou, N | 1 |
| Ben Abdelghani, M; Blanc, JF; Boilève, A; Castanié, H; Cohen, R; Dahan, L; Garcia-Larnicol, ML; Gougis, P; Hilmi, M; Metges, JP; Neuzillet, C; Rousseau, B; Tougeron, D; Tournigand, C; Turpin, A; Vernerey, D | 1 |
| Carrato, A; Feliu, J; Garcia-Carbonero, R; Gómez-España, MA; Martín, AM; Maurel, J; Mercadé, TM; Montes, AF; Pazo-Cid, R; Vera, R | 1 |
| Goff, LW; Roth, MT | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Uwagawa, T; Yanaga, K | 1 |
| Choi, J; Choi, Y; Haam, S; Huh, YM; Kim, HO; Lee, DK; Noh, I | 1 |
| Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S | 1 |
| Hoque, A; Jones, DV; Lozano, R; Markowitz, A; Patt, YZ | 1 |
| Androulakis, N; Aravantinos, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Papakostas, P; Samelis, G; Sarra, E; Souglakos, J | 1 |
1 review(s) available for paclitaxel and Biliary Tract Cancer
| Article | Year |
|---|---|
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
6 trial(s) available for paclitaxel and Biliary Tract Cancer
| Article | Year |
|---|---|
Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Young Adult | 2023 |
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel | 2021 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids | 2002 |
Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Drug Administration Schedule; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Neuromuscular Diseases; Paclitaxel; Remission Induction | 1996 |
First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Biliary Tract Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids; Treatment Outcome | 2001 |
4 other study(ies) available for paclitaxel and Biliary Tract Cancer
| Article | Year |
|---|---|
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Propensity Score | 2022 |
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Humans; Irinotecan; Leucovorin; Medical Oncology; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Quality of Life; Societies, Medical; Spain | 2021 |
Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP.
Topics: Albumins; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel | 2019 |
Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hyaluronan Receptors; Nanoparticles; Paclitaxel | 2015 |